Elicio Therapeutics, Inc.

For the period ended Sep 30, 2025. Filed Nov 13, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2025 · Filed Nov 13, 2025

ELTX$1.61-2.1%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited)

Condensed Consolidated Statements of Operations and Comprehensive Loss

(in thousands, except share and per share amounts)

	Three Months Ended September 30,		Nine Months Ended September 30,
	2025	2024	2025	2024
Operating expenses:
Research and development	$5,039	$7,208	$19,823	$22,947
General and administrative	3,006	3,136	9,049	8,563
Total operating expenses	8,045	10,344	28,872	31,510
Loss from operations	(8,045)	(10,344)	(28,872)	(31,510)
Other (expense) income
Change in fair value of warrant liabilities	(1,811)	(5,617)	(3,177)	(3,279)
Loss on issuance of pre-funded warrants	—	(2,924)	—	(3,502)
Gain on sale of equipment	—	—	—	3
Foreign exchange transaction (loss) gain	—	(1)	—	143
Grant income	—	—	415	—
Interest income	199	185	577	472
Interest expense	(426)	(137)	(796)	(221)
Total other (expense), net	(2,038)	(8,494)	(2,981)	(6,384)
Net loss	(10,083)	(18,838)	(31,853)	(37,894)
Other comprehensive income (loss):
Foreign currency translation adjustment	39	36	144	(5)
Comprehensive loss	$(10,044)	$(18,802)	$(31,709)	$(37,899)
Net loss per common share, basic and diluted	$(0.60)	$(1.39)	$(2.09)	$(3.23)
Weighted average common shares and pre-funded warrants outstanding, basic and diluted	16,692,476	13,582,345	15,247,864	11,720,527

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.